Item
VITAMIN C (ASCORBIC ACID) (1118)
Ascorbic Acid- 100%
Nutrient / Vitamin
Attributes
- Gluten-free
- Halal
- Ingredient declaration
- Kosher
- PHO-free
- Vegan
- Non-GMO
Locations
| Location name | Address |
|---|---|
| CSPC INNOVATION PHARMACEUTICAL | No. 36 Fuqiang Western Rd Luancheng Cty Shijazhaung City, Hebei Province NA CHN |
| CSPC WEISHENG PHARMACEUTICAL | No. 236 Huange Street High-Tech Development Zone Shijiazhuang, HE 50035 CHN |
| Jiangsu Jiangshan Pharmaceutical Co., Ltd. | No. 61, Jiangshan Road Jingjiang, JS 214500 CHN |
| Luwei Pharmaceutical Group Co., Ltd. | Shuangfeng Industrial Park Zibo City, SD 255190 CHN |
| Northeast Pharmaceutical Group Co., Ltd. No.29 | No. 29 Shenxiliu Dong Road Economic Technological Development District, Shenyang xxx CHN |
| Northeast Pharmaceutical Group Co., Ltd. No.37 | No. 37, Zhonggong Bei Street Tiexi District, Shenyang, Liaoning Province xxx CHN |
| Prinova USA | 6525 Muirfield Drive. Hanover Park, IL 60133 |
| Shandong Xinhua Pharmaceutical Co., Ltd. | East Chemical Zone of Zibo High and New Technologic Devolpment Zone Zibo City, Shandong Province xxx CHN |
Documents
| Type | Location | File name | Effective | Expiration |
|---|---|---|---|---|
| Recall/Emergency/Contact List | CSPC WEISHENG PHARMACEUTICAL | 2023 contact info.pdf | 12/9/2024 | 12/9/2025 |
| 3rd Party Audit Certificate | CSPC WEISHENG PHARMACEUTICAL | 3rd Party Food Safety Certificate - 2024-12-06T084029.674.pdf | 5/19/2024 | 5/27/2025 |
| GFSI Certificate | CSPC WEISHENG PHARMACEUTICAL | 3rd Party Food Safety Certificate - 2024-12-09T115813.869.pdf | 5/19/2024 | 5/27/2025 |
| HACCP | Prinova USA | 3rd party-Haccp doc - Prinova.pdf | 6/9/2021 | 6/8/2024 |
| HACCP | Northeast Pharmaceutical Group Co., Ltd. No.37 | 3rd party-Haccp doc - Prinova.pdf | 6/5/2021 | 6/4/2024 |
| HACCP | Luwei Pharmaceutical Group Co., Ltd. | 3rd party-Haccp doc - Prinova.pdf | 8/16/2024 | 8/16/2027 |
| HARPC Food Safety Plan (Item) | Luwei Pharmaceutical Group Co., Ltd. | 3rd party-Haccp doc - Prinova.pdf | 8/16/2024 | 8/16/2027 |
| HACCP | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | 3rd party-Haccp doc - Prinova.pdf | 8/13/2024 | 8/13/2027 |
| HACCP | Northeast Pharmaceutical Group Co., Ltd. No.29 | 3rd party-Haccp doc - Prinova.pdf | 8/13/2024 | 8/13/2027 |
| HARPC Food Safety Plan (Item) | Northeast Pharmaceutical Group Co., Ltd. No.29 | 3rd party-Haccp doc - Prinova.pdf | 8/13/2024 | 8/13/2027 |
| 3rd Party Audit Report | CSPC WEISHENG PHARMACEUTICAL | 3rd party-Haccp doc - Prinova.pdf | 12/6/2024 | 12/31/2025 |
| Bioterrorism Letter | CSPC WEISHENG PHARMACEUTICAL | 3rd party-Haccp doc - Prinova.pdf | 12/6/2024 | 12/6/2026 |
| 3rd Party Audit Corrective Action Plan | CSPC WEISHENG PHARMACEUTICAL | 3rd party-Haccp doc - Prinova.pdf | 12/6/2024 | 12/31/2025 |
| Allergen Control Policy | CSPC WEISHENG PHARMACEUTICAL | 3rd party-Haccp doc - Prinova.pdf | 12/6/2024 | 12/6/2026 |
| CA Transparency Act | CSPC WEISHENG PHARMACEUTICAL | 3rd party-Haccp doc - Prinova.pdf | 12/6/2024 | 12/6/2026 |
| CTPAT | CSPC WEISHENG PHARMACEUTICAL | 3rd party-Haccp doc - Prinova.pdf | 12/6/2024 | 12/6/2025 |
| Environmental Policy | CSPC WEISHENG PHARMACEUTICAL | 3rd party-Haccp doc - Prinova.pdf | 12/6/2024 | 12/6/2025 |
| Ethical Code of Conduct | CSPC WEISHENG PHARMACEUTICAL | 3rd party-Haccp doc - Prinova.pdf | 12/6/2024 | 12/6/2026 |
| FDA Registration | CSPC WEISHENG PHARMACEUTICAL | 3rd party-Haccp doc - Prinova.pdf | 12/6/2024 | 12/31/2025 |
| Food Defense Plan Statement | CSPC WEISHENG PHARMACEUTICAL | 3rd party-Haccp doc - Prinova.pdf | 12/6/2024 | 12/6/2026 |
| GFSI Audit Report | CSPC WEISHENG PHARMACEUTICAL | 3rd party-Haccp doc - Prinova.pdf | 12/6/2024 | 12/31/2025 |
| GFSI Corrective Action | CSPC WEISHENG PHARMACEUTICAL | 3rd party-Haccp doc - Prinova.pdf | 12/6/2024 | 12/31/2025 |
| HACCP Plan (Facility) | CSPC WEISHENG PHARMACEUTICAL | 3rd party-Haccp doc - Prinova.pdf | 12/6/2024 | 12/6/2026 |
| HARPC Food Safety Plan (Facility) | CSPC WEISHENG PHARMACEUTICAL | 3rd party-Haccp doc - Prinova.pdf | 12/6/2024 | 12/6/2027 |
| HARPC Food Safety Plan (Item) | CSPC WEISHENG PHARMACEUTICAL | 3rd party-Haccp doc - Prinova.pdf | 12/6/2024 | 12/6/2027 |
| Organizational Chart | CSPC WEISHENG PHARMACEUTICAL | 3rd party-Haccp doc - Prinova.pdf | 12/6/2024 | 12/6/2025 |
| Recall Plan | CSPC WEISHENG PHARMACEUTICAL | 3rd party-Haccp doc - Prinova.pdf | 12/6/2024 | 12/6/2025 |
| Supplier Approval Program Statement | CSPC WEISHENG PHARMACEUTICAL | 3rd party-Haccp doc - Prinova.pdf | 12/6/2024 | 12/6/2025 |
| HACCP | CSPC WEISHENG PHARMACEUTICAL | 3rd party-Haccp doc - Prinova.pdf | 4/16/2025 | 4/15/2028 |
| Gluten | CSPC WEISHENG PHARMACEUTICAL | Allergen - 2024-05-15T162142.250.pdf | 9/9/2023 | 9/8/2025 |
| Gluten | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | Allergen - 2024-09-20T145316.129.pdf | 6/14/2024 | 6/14/2026 |
| Allergens EU/UK | CSPC WEISHENG PHARMACEUTICAL | Allergens EU/UK.pdf | 12/6/2024 | 12/6/2026 |
| Allergens | Northeast Pharmaceutical Group Co., Ltd. No.37 | Allergens.pdf | 5/18/2023 | 5/17/2025 |
| Allergens | Northeast Pharmaceutical Group Co., Ltd. No.29 | Allergens.pdf | 7/31/2023 | 7/30/2025 |
| Allergens | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | Allergens.pdf | 6/3/2024 | 6/3/2026 |
| Allergens | CSPC WEISHENG PHARMACEUTICAL | Allergens.pdf | 6/4/2024 | 6/4/2026 |
| Allergens | Luwei Pharmaceutical Group Co., Ltd. | Allergens.pdf | 12/30/2024 | 12/30/2026 |
| CoA Sample | CSPC WEISHENG PHARMACEUTICAL | Approved COA Template - 2024-09-16T124040.208.pdf | 1/23/2024 | 1/22/2026 |
| CoA Sample | Luwei Pharmaceutical Group Co., Ltd. | Approved COA Template (11).pdf | 4/26/2024 | 4/26/2026 |
| GMO | Prinova USA | Ascorbic acid (613) CSPC Weisheng - GMO Status (CN)v2 (1).pdf | 6/30/2021 | 6/30/2024 |
| Natural | CSPC WEISHENG PHARMACEUTICAL | Ascorbic acid (613) CSPC Weisheng - Regulatory Information Sheet (CN) v3 (5).pdf | 6/30/2023 | 6/29/2024 |
| Organic | CSPC WEISHENG PHARMACEUTICAL | Ascorbic acid (613) CSPC Weisheng - Regulatory Information Sheet (CN) v3 (5).pdf | 6/30/2023 | 6/29/2024 |
| CoA Sample | Northeast Pharmaceutical Group Co., Ltd. No.37 | Ascorbic acid (613) NEGPF No.29 - COA.pdf | 3/15/2022 | 3/14/2024 |
| CoA Sample | Northeast Pharmaceutical Group Co., Ltd. No.29 | Ascorbic acid (613) NEGPF No.29 - COA.pdf | 7/10/2024 | 7/10/2026 |
| Gluten | Northeast Pharmaceutical Group Co., Ltd. No.29 | Ascorbic acid 613 NEGPF No29 - Allergen Status CN amended.pdf | 3/15/2021 | 3/15/2022 |
| Heavy Metal | Northeast Pharmaceutical Group Co., Ltd. No.37 | Ascorbic acid 613 NEGPF No29 - Contaminants amp Impurities CN amended.pdf | 3/15/2021 | 3/15/2023 |
| HACCP Process Flow Diagram | Northeast Pharmaceutical Group Co., Ltd. No.29 | Ascorbic acid 613 NEGPF No29 - Flow chart 1.pdf | 3/15/2021 | 3/15/2023 |
| HACCP Process Flow Diagram | Northeast Pharmaceutical Group Co., Ltd. No.37 | Ascorbic acid 613 NEGPF No29 - Flow chart.pdf | 3/15/2021 | 3/15/2023 |
| GMO | Northeast Pharmaceutical Group Co., Ltd. No.29 | Ascorbic acid 613 NEGPF No29 - GMO Status CN-filled 1.pdf | 3/15/2021 | 3/15/2023 |
| Lot Code | Northeast Pharmaceutical Group Co., Ltd. No.37 | Ascorbic acid 613 NEGPF No29 - Packaging Declaration CN amended 1.pdf | 3/15/2021 | 3/14/2024 |
| Lot Code | Northeast Pharmaceutical Group Co., Ltd. No.29 | Ascorbic acid 613 NEGPF No29 - Packaging Declaration CN amended 2.pdf | 3/15/2021 | 3/14/2024 |
| Label Sample | Northeast Pharmaceutical Group Co., Ltd. No.29 | Ascorbic acid 613 NEGPF No29 - Packaging Declaration CN amended 4.pdf | 3/15/2022 | 3/15/2023 |
| Label Sample | Northeast Pharmaceutical Group Co., Ltd. No.37 | Ascorbic acid 613 NEGPF No29 - Packaging Declaration CN amended 5.pdf | 3/15/2022 | 3/15/2023 |
| Safety Data Sheet (SDS) | Northeast Pharmaceutical Group Co., Ltd. No.37 | Ascorbic acid 613 NEGPF No29 - SDS 4.pdf | 2/21/2021 | 2/21/2024 |
| Shelf Life | Northeast Pharmaceutical Group Co., Ltd. No.37 | Ascorbic acid 613 NEGPF No29 - Specification F 2.pdf | 3/15/2021 | 3/14/2024 |
| Shelf Life | Northeast Pharmaceutical Group Co., Ltd. No.29 | Ascorbic acid 613 NEGPF No29 - Specification F.pdf | 1/1/2021 | 1/1/2023 |
| WADA/NSF/NFL Statement | CSPC WEISHENG PHARMACEUTICAL | Banned Substance (5).pdf | 7/12/2024 | 7/12/2026 |
| BSE - TSE | Luwei Pharmaceutical Group Co., Ltd. | BSE-TSE (26).pdf | 4/9/2024 | 4/9/2027 |
| Insurance | CSPC WEISHENG PHARMACEUTICAL | Certificate of Insurance doc - Prinova 2024.pdf | 10/1/2024 | 10/1/2025 |
| CoA Sample | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | COA75720393.pdf | 3/22/2021 | 3/22/2023 |
| Heavy Metal | Luwei Pharmaceutical Group Co., Ltd. | Contaminants and Impurities - 2024-01-10T132329.441.pdf | 5/29/2023 | 5/28/2025 |
| Melamine | CSPC WEISHENG PHARMACEUTICAL | Contaminants and Impurities - 2024-02-05T125133.454.pdf | 7/9/2023 | 7/8/2024 |
| Melamine | Luwei Pharmaceutical Group Co., Ltd. | Contaminants and Impurities - 2024-07-02T142140.577.pdf | 4/6/2024 | 4/6/2025 |
| Pesticide | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | Contaminants and Impurities - 2024-09-20T151434.008.pdf | 6/12/2024 | 6/12/2026 |
| Residual Statement | Luwei Pharmaceutical Group Co., Ltd. | Contaminants and Impurities - 2025-04-14T155359.047.pdf | 4/14/2025 | 4/14/2026 |
| Residual Statement | CSPC WEISHENG PHARMACEUTICAL | Contaminants and Impurities - 2025-04-14T155359.047.pdf | 4/14/2025 | 4/14/2026 |
| Heavy Metal | CSPC WEISHENG PHARMACEUTICAL | Contaminants and Impurities (26).pdf | 7/12/2024 | 7/12/2026 |
| Pesticide | CSPC WEISHENG PHARMACEUTICAL | Contaminants and Impurities (26).pdf | 7/12/2024 | 7/12/2026 |
| Heavy Metal | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | Contaminants and Impurities (29).pdf | 7/24/2024 | 7/24/2026 |
| Country of Origin EU/UK | CSPC WEISHENG PHARMACEUTICAL | Country of Origin EU/UK.pdf | 4/25/2022 | 4/24/2025 |
| Country of Origin | Northeast Pharmaceutical Group Co., Ltd. No.37 | Country of Origin.pdf | 4/20/2022 | 4/19/2025 |
| Country of Origin | Luwei Pharmaceutical Group Co., Ltd. | Country of Origin.pdf | 7/10/2024 | 7/10/2027 |
| Country of Origin | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | Country of Origin.pdf | 8/12/2024 | 8/12/2027 |
| Country of Origin | Northeast Pharmaceutical Group Co., Ltd. No.29 | Country of Origin.pdf | 9/13/2024 | 9/13/2027 |
| Country of Origin | CSPC WEISHENG PHARMACEUTICAL | Country of Origin.pdf | 1/27/2025 | 1/27/2028 |
| Vegan/Vegetarian Statement | Luwei Pharmaceutical Group Co., Ltd. | Dietary Status (55).pdf | 4/2/2024 | 4/2/2026 |
| No Animal Ingredient Statement | Luwei Pharmaceutical Group Co., Ltd. | Dietary Status (90).pdf | 4/21/2025 | 4/21/2026 |
| Dietary Supplement Questionnaire | CSPC WEISHENG PHARMACEUTICAL | Dietary Supplement Questionnaire.pdf | 9/3/2021 | 9/3/2022 |
| HACCP Process Flow Diagram | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | Flow Chart - 2024-02-05T114158.527.pdf | 9/5/2022 | 9/4/2024 |
| HACCP Process Flow Diagram | CSPC WEISHENG PHARMACEUTICAL | Flow Chart - 2024-08-12T154125.787.pdf | 4/12/2024 | 4/12/2026 |
| HACCP Process Flow Diagram | Luwei Pharmaceutical Group Co., Ltd. | Flow Chart - 2025-04-09T163554.498.pdf | 4/9/2025 | 4/9/2027 |
| Animal Testing Statement | Luwei Pharmaceutical Group Co., Ltd. | Free of Statement (3).pdf | 4/7/2021 | 4/6/2024 |
| FSVP Assessment Form | Luwei Pharmaceutical Group Co., Ltd. | FSVP Assessment Form.pdf | 2/17/2025 | 2/17/2026 |
| FSVP Assessment Form | CSPC WEISHENG PHARMACEUTICAL | FSVP Assessment Form.pdf | 2/28/2025 | 2/28/2026 |
| Shelf Life | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | FW_ VC Ascorbic Acid Regular Spec change 5015838 2 4.pdf | 3/16/2020 | 3/16/2023 |
| GMO | CSPC WEISHENG PHARMACEUTICAL | GMO (17).pdf | 7/12/2024 | 7/12/2026 |
| GMO | Luwei Pharmaceutical Group Co., Ltd. | GMO-Non-GMO Project (92).pdf | 3/24/2025 | 12/22/2025 |
| Halal | Northeast Pharmaceutical Group Co., Ltd. No.29 | Halal Certificate - 2023-09-11T134701.632.pdf | 12/7/2022 | 12/6/2026 |
| Halal | Luwei Pharmaceutical Group Co., Ltd. | Halal Certificate - 2024-07-02T151124.953.pdf | 6/19/2024 | 6/19/2027 |
| Halal | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | Halal Certificate - 2024-10-21T135935.300.pdf | 3/31/2024 | 3/30/2027 |
| Halal | CSPC WEISHENG PHARMACEUTICAL | Halal Certificate (87).pdf | 7/28/2022 | 7/27/2026 |
| Ingredient Statement | Luwei Pharmaceutical Group Co., Ltd. | Ingredient Breakdown_Declaration - 2025-04-16T123600.417.pdf | 4/16/2025 | 4/15/2028 |
| Item Questionnaire | Northeast Pharmaceutical Group Co., Ltd. No.29 | Item Questionnaire.pdf | 7/26/2021 | 7/25/2024 |
| Item Questionnaire | Northeast Pharmaceutical Group Co., Ltd. No.37 | Item Questionnaire.pdf | 4/20/2023 | 4/19/2026 |
| Item Questionnaire | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | Item Questionnaire.pdf | 9/20/2024 | 9/20/2027 |
| Item Questionnaire | Luwei Pharmaceutical Group Co., Ltd. | Item Questionnaire.pdf | 10/21/2024 | 10/21/2027 |
| Item Questionnaire | CSPC WEISHENG PHARMACEUTICAL | Item Questionnaire.pdf | 4/7/2025 | 4/6/2028 |
| Kosher | CSPC WEISHENG PHARMACEUTICAL | Kosher Certificate - 2024-09-04T161304.716.pdf | 8/27/2024 | 8/31/2025 |
| Kosher | Northeast Pharmaceutical Group Co., Ltd. No.29 | Kosher Certificate - 2024-10-21T100250.580.pdf | 9/12/2024 | 9/30/2025 |
| Kosher | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | Kosher Certificate - 2025-01-16T154411.299.pdf | 1/16/2025 | 12/31/2025 |
| Kosher | Luwei Pharmaceutical Group Co., Ltd. | Kosher Certificate - 2025-03-26T095658.242.pdf | 3/13/2025 | 3/31/2026 |
| Kosher | Northeast Pharmaceutical Group Co., Ltd. No.37 | Kosher Certificate 171.pdf | 9/30/2022 | |
| Label Sample | CSPC WEISHENG PHARMACEUTICAL | Label - 2025-04-16T093220.469.pdf | 4/16/2025 | 4/16/2026 |
| Lot Code | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | Lot Code Explanation (62).pdf | 3/3/2025 | 3/2/2028 |
| Gluten | Luwei Pharmaceutical Group Co., Ltd. | Luwei - Ascorbic Acid - Allergen Status & Gluten-free.pdf | 4/14/2025 | 4/14/2027 |
| Pesticide | Luwei Pharmaceutical Group Co., Ltd. | Luwei - Ascorbic Acid - Contaminants and Impurities.pdf | 4/14/2025 | 4/14/2027 |
| National Bioengineered Food Disclosure Standard (Simplified) | Luwei Pharmaceutical Group Co., Ltd. | National Bioengineered Food Disclosure Standard (Simplified).pdf | 8/17/2022 | 8/16/2025 |
| National Bioengineered Food Disclosure Standard (Simplified) | CSPC WEISHENG PHARMACEUTICAL | National Bioengineered Food Disclosure Standard (Simplified).pdf | 5/15/2024 | 5/15/2027 |
| Nutrition EU/UK | CSPC WEISHENG PHARMACEUTICAL | Nutrition EU/UK.pdf | 4/25/2022 | 4/24/2025 |
| Nutrition | Northeast Pharmaceutical Group Co., Ltd. No.29 | Nutrition.pdf | 9/29/2021 | 9/28/2024 |
| Nutrition | Northeast Pharmaceutical Group Co., Ltd. No.37 | Nutrition.pdf | 4/20/2023 | 4/19/2026 |
| Nutrition | CSPC WEISHENG PHARMACEUTICAL | Nutrition.pdf | 7/22/2024 | 7/22/2027 |
| Nutrition | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | Nutrition.pdf | 9/20/2024 | 9/20/2027 |
| Nutrition | Luwei Pharmaceutical Group Co., Ltd. | Nutrition.pdf | 10/30/2024 | 10/30/2027 |
| Sewage Statement | CSPC WEISHENG PHARMACEUTICAL | Organic Compliance - 2024-08-28T114935.020.pdf | 3/10/2024 | 3/10/2026 |
| Organic | Luwei Pharmaceutical Group Co., Ltd. | Organic Compliance - 2025-03-19T131516.244.pdf | 3/19/2025 | 3/19/2027 |
| Sewage Statement | Luwei Pharmaceutical Group Co., Ltd. | Organic Compliance - 2025-03-26T104834.973.pdf | 3/26/2025 | 3/26/2027 |
| Natural | Luwei Pharmaceutical Group Co., Ltd. | Organic Compliance - 2025-03-26T105726.879.pdf | 3/26/2025 | 3/26/2026 |
| Irradiation Status Statement | Luwei Pharmaceutical Group Co., Ltd. | Organic Compliance - 2025-04-09T163732.098.pdf | 4/9/2025 | 4/9/2027 |
| EtO Statement | Luwei Pharmaceutical Group Co., Ltd. | Organic Compliance - 2025-04-09T163732.098.pdf | 4/9/2025 | 4/9/2027 |
| Food Contact Packaging Certificate of Compliance | Luwei Pharmaceutical Group Co., Ltd. | Packaging Declaration - 2024-07-02T143151.767.pdf | 4/6/2023 | 4/5/2025 |
| Lot Code | CSPC WEISHENG PHARMACEUTICAL | Packaging Declaration - 2025-01-24T093753.436.pdf | 4/12/2024 | 4/12/2027 |
| Food Contact Packaging Certificate of Compliance | CSPC WEISHENG PHARMACEUTICAL | Packaging Declaration - 2025-02-03T160609.551.pdf | 4/12/2024 | 4/12/2026 |
| Lot Code | Luwei Pharmaceutical Group Co., Ltd. | Packaging Declaration - 2025-03-26T103219.133.pdf | 3/26/2025 | 3/25/2028 |
| Label Sample | Luwei Pharmaceutical Group Co., Ltd. | Packaging Declaration - 2025-04-09T163247.938.pdf | 4/9/2025 | 4/9/2026 |
| No Animal Ingredient Statement | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | Product Data Sheet - 2023-03-27T151007.710.pdf | 1/8/2023 | 1/8/2024 |
| Ingredient Statement | CSPC WEISHENG PHARMACEUTICAL | Product Data Sheet - 2024-07-22T093735.121.pdf | 4/12/2024 | 4/12/2027 |
| Shelf Life | CSPC WEISHENG PHARMACEUTICAL | Product Data Sheet - 2025-04-07T153906.694.pdf | 4/7/2025 | 4/6/2028 |
| WADA/NSF/NFL Statement | Luwei Pharmaceutical Group Co., Ltd. | Product Data Sheet (47).pdf | 1/8/2021 | 1/8/2024 |
| Ingredient Statement | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | Product Data Sheet (50).pdf | 8/1/2022 | 8/1/2023 |
| GMO | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | Product Data Sheet 65.pdf | 1/8/2021 | 1/8/2023 |
| Irradiation Status Statement | CSPC WEISHENG PHARMACEUTICAL | Production Process (75).pdf | 4/12/2024 | 4/12/2026 |
| EtO Statement | CSPC WEISHENG PHARMACEUTICAL | Production Process (76).pdf | 4/12/2024 | 4/12/2026 |
| California Prop. 65 | CSPC WEISHENG PHARMACEUTICAL | Prop 65 - 2025-03-26T124544.386.pdf | 3/26/2025 | 3/26/2027 |
| California Prop. 65 | Luwei Pharmaceutical Group Co., Ltd. | Prop 65 - 2025-04-21T124628.340.pdf | 4/21/2025 | 4/21/2027 |
| California Prop. 65 | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | Prop 65 (3).pdf | 8/4/2023 | 8/3/2025 |
| No Animal Ingredient Statement | CSPC WEISHENG PHARMACEUTICAL | RE_ Updated docs for VC ascorbic 10036 ex CSPC Weisheng 5 (5).pdf | 5/8/2023 | 5/7/2024 |
| Irradiation Status Statement | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | Regulatory Information Sheet - 2024-02-07T121616.925.pdf | 8/3/2022 | 8/2/2024 |
| GRAS/NDI/ODI Statement | Luwei Pharmaceutical Group Co., Ltd. | Regulatory Information Sheet - 2024-07-19T141302.414.pdf | 10/10/2023 | 10/9/2026 |
| Vegan/Vegetarian Statement | CSPC WEISHENG PHARMACEUTICAL | Regulatory Information Sheet - 2024-07-31T093141.999.pdf | 4/12/2024 | 4/12/2026 |
| BSE - TSE | CSPC WEISHENG PHARMACEUTICAL | Regulatory Information Sheet - 2024-12-09T140019.740.pdf | 4/12/2024 | 4/12/2027 |
| Animal Testing Statement | CSPC WEISHENG PHARMACEUTICAL | Regulatory Information Sheet - 2025-01-13T114358.024.pdf | 4/12/2024 | 4/12/2026 |
| Safety Data Sheet (SDS) | Luwei Pharmaceutical Group Co., Ltd. | SDS - 2024-05-20T153709.178.pdf | 1/1/2024 | 12/31/2025 |
| Safety Data Sheet (SDS) | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | SDS - 2024-09-20T144602.275.pdf | 4/18/2024 | 4/18/2027 |
| Safety Data Sheet (SDS) | Northeast Pharmaceutical Group Co., Ltd. No.29 | SDS - 2025-01-22T152433.545.pdf | 1/3/2024 | 1/2/2027 |
| Safety Data Sheet (SDS) | CSPC WEISHENG PHARMACEUTICAL | SDS - 2025-03-03T113657.201.pdf | 3/3/2025 | 3/2/2028 |
| Product Specification Sheet | CSPC WEISHENG PHARMACEUTICAL | Spec for Ascorbic Acid (Export food Grade)for prinova US_CSPC Weisheng_Apr2024.pdf | 7/12/2024 | 7/12/2027 |
| Suitability Requirements | Northeast Pharmaceutical Group Co., Ltd. No.29 | Suitability Requirements.pdf | 7/29/2021 | 7/28/2024 |
| Suitability Requirements | Northeast Pharmaceutical Group Co., Ltd. No.37 | Suitability Requirements.pdf | 9/2/2022 | 9/1/2025 |
| Suitability Requirements | CSPC WEISHENG PHARMACEUTICAL | Suitability Requirements.pdf | 10/26/2022 | 10/25/2025 |
| Suitability Requirements | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | Suitability Requirements.pdf | 9/20/2024 | 9/20/2027 |
| Suitability Requirements | Luwei Pharmaceutical Group Co., Ltd. | Suitability Requirements.pdf | 10/7/2024 | 10/7/2027 |
| GRAS/NDI/ODI Statement | CSPC WEISHENG PHARMACEUTICAL | US Regulatory Status - 2024-07-22T120005.620.pdf | 7/22/2024 | 7/22/2027 |
| GRAS/NDI/ODI Statement | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | US Regulatory Status (34).pdf | 12/2/2022 | 12/1/2025 |
| Product Specification Sheet | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | US SPECIFICATION - 2023-03-06T122850.232.pdf | 12/17/2020 | 12/17/2023 |
| Shelf Life | Luwei Pharmaceutical Group Co., Ltd. | US SPECIFICATION - 2024-07-02T153709.326.pdf | 10/8/2023 | 10/7/2026 |
| Product Specification Sheet | Luwei Pharmaceutical Group Co., Ltd. | US SPECIFICATION - 2024-10-07T091438.006.pdf | 10/8/2023 | 10/7/2026 |
| Sewage Statement | Northeast Pharmaceutical Group Co., Ltd. No.29 | Vit C - NEPG29 - Organic Use.pdf | 8/3/2021 | 8/3/2023 |
| California Prop. 65 | Northeast Pharmaceutical Group Co., Ltd. No.29 | Vit C - NEPG29 - Prop 65.pdf | 8/3/2021 | 8/3/2023 |
| Phthalate Esters Letter | Luwei Pharmaceutical Group Co., Ltd. | VIT C Regular (613) Shandong Luwei - Contaminants & Impurities (CN)Amended (8).pdf | 6/17/2022 | 6/17/2023 |
